Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Neuroendocrine Tumors
DRUG: Indium-111 pentetreotide
Change in solid tumor dimensions by CT scan., Change in diameters of measurable lesions on CT using RECIST. and will be classified into 4 groups.

1. Complete response
2. Partial response
3. No change or stable disease
4. Progression, Baseline to post treatment CT scan performed 2-4 days after each cycle and 12and 24 weeks after treatments
Frequency and severity of adverse events, Frequency and severity of adverse events. All adverse events will be graded using NCI common toxicities criteria, up to 6 months following the last cycle of therap
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.